Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rüegg, S. J.
Right arrow Articles by Steck, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rüegg, S. J.
Right arrow Articles by Steck, A. J.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Peripheral neuropathy
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;63:2178-2179
© 2004 American Academy of Neurology
Brief Communications

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

Stephan J. Rüegg, MD, Peter Fuhr, MD and Andreas J. Steck, MD

From the Department of Neurology, University Hospital, Basel, Switzerland.

Address correspondence and reprint requests to Dr. Stephan Rüegg, Department of Neurology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland; e-mail: srueegg{at}uhbs.ch

The authors report a patient with anti-GM1 antibody-negative multifocal motor neuropathy (MMN) who was increasingly less responsive to IV immunoglobulins (IVIgs). Five yearly courses of the monoclonal anti-CD20 antibody rituximab were well tolerated and extended the interval of IVIg administration from 7 to 12 days (corresponding to 42% reduction of IVIg) during this period. Rituximab may be a benefit for patients with MMN.

Received May 17, 2004. Accepted in final form July 22, 2004.

Presented in part at the annual meeting of the Swiss Society for Clinical Neurophysiology, Basel, Switzerland, April 22–24, 2004.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. C. Novak, A. E. Lovett-Racke, and M. K. Racke
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol, September 1, 2008; 65(9): 1162 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
Y A Rajabally
Multifocal motor neuropathy: review of a treatable immune mediated disorder
Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. J. Triggs and D. Cros
Case 40-2007 -- A 38-Year-Old Man with Weakness in the Hands
N. Engl. J. Med., December 27, 2007; 357(26): 2707 - 2715.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. Renaud, P. Fuhr, M. Gregor, K. Schweikert, D. Lorenz, C. Daniels, G. Deuschl, A. Gratwohl, and A. J. Steck
High-dose rituximab and anti-MAG-associated polyneuropathy
Neurology, March 14, 2006; 66(5): 742 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
O. Stuve, S. Cepok, B. Elias, A. Saleh, H.-P. Hartung, B. Hemmer, and B. C. Kieseier
Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis
Arch Neurol, October 1, 2005; 62(10): 1620 - 1623.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.